TY - JOUR
T1 - Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
AU - Reynolds, Catherine J.
AU - Pade, Corinna
AU - Gibbons, Joseph M.
AU - Butler, David K.
AU - Otter, Ashley D.
AU - Menacho, Katia
AU - Fontana, Marianna
AU - Smit, Angelique
AU - Sackville-West, Jane E.
AU - Cutino-Moguel, Teresa
AU - Maini, Mala K.
AU - Chain, Benjamin
AU - Noursadeghi, Mahdad
AU - Brooks, Tim
AU - Semper, Amanda
AU - Manisty, Charlotte
AU - Treibel, Thomas A.
AU - Moon, James C.
AU - Valdes, Ana M.
AU - McKnight, Áine
AU - Altmann, Daniel M.
AU - Boyton, Rosemary
AU - UK COVIDsortium Immune Correlates Network
AU - UK COVIDsortium Investigators
A2 - Hickling, Lauren M.
N1 - Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper or the supplementary materials. SARS-CoV-2 nucleoprotein (100982) and SARS-CoV-2 spike (100979) are available from P. Cherepanov, Francis Crick Institute, UK, under a material transfer agreement with Centre for AIDS Reagents (CFAR), National Institute for Biological Standards and Control (NIBSC), UK. The SARS-CoV-2 B.1.1.7 isolate was obtained from NIBSC, thanks to the contribution of PHE Porton Down and S. Funnell. The nCoV19 isolate/UK ex South African/2021 lineage B.1.351 EVA catalog code 04V-04071 was obtained from European Virus Archive Global, PHE Porton Down. The SARS-CoV-2 Wuhan-Hu-1 Human 2019-nCoV Isolate EVA catalog code 026V-03883 was obtained from European Virus Archive Global, Charité – Universitätsmedizin Berlin.
PY - 2021/6/25
Y1 - 2021/6/25
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has coincided with the spread of variants of concern. We investigated whether single-dose vaccination, with or without prior infection, confers cross-protective immunity to variants. We analyzed T and B cell responses after first-dose vaccination with the Pfizer/BioNTech messenger RNA vaccine BNT162b2 in health care workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody-secreting memory B cell response to the spike protein, and neutralizing antibodies effective against variants B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated, or unchanged T cell responses, depending on human leukocyte antigen (HLA) polymorphisms. Single-dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has coincided with the spread of variants of concern. We investigated whether single-dose vaccination, with or without prior infection, confers cross-protective immunity to variants. We analyzed T and B cell responses after first-dose vaccination with the Pfizer/BioNTech messenger RNA vaccine BNT162b2 in health care workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody-secreting memory B cell response to the spike protein, and neutralizing antibodies effective against variants B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated, or unchanged T cell responses, depending on human leukocyte antigen (HLA) polymorphisms. Single-dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants.
UR - http://www.scopus.com/inward/record.url?scp=85108653630&partnerID=8YFLogxK
U2 - 10.1126/science.abh1282
DO - 10.1126/science.abh1282
M3 - Article
C2 - 33931567
AN - SCOPUS:85108653630
SN - 0036-8075
VL - 372
SP - 1418
EP - 1423
JO - Science
JF - Science
IS - 6549
ER -
